UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Biodiversity inhibits parasites: Broad evidence for the dilution effect

Proceedings of the National Academy of Sciences - PNAS, 2015-07, Vol.112 (28), p.8667-8671

2015

Volltextzugriff (PDF)

Determination of Paraphenylenediamine in Hair Dyes Formulation Using Visible Spectroscopy

INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE, 2023-12, Vol.14 (4), p.917-920

2023

Volltextzugriff (PDF)

Submicron Emulsion - A Novel and Versatile Paradigm for Delivery of Therapeutics for Bioavailability Enhancement

International journal of pharmaceutical sciences review and research, 2022-04, p.122-125

2022

Volltextzugriff (PDF)

Development of protease resistant and non-cytotoxic Jelleine analogs with enhanced broad spectrum antimicrobial efficacy

Biochimica et biophysica acta. Biomembranes, 2024-08, Vol.1866 (6), p.184336, Article 184336

2024

Volltextzugriff (PDF)

Removal of pain-relieving drugs from aqueous solutions using Octolig and selected metalloligs

Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering, 2015-07, Vol.50 (8), p.788-793

2015

Volltextzugriff (PDF)

Wavelet-based analysis of circadian behavioral rhythms

Methods in enzymology, 2015-01, Vol.551, p.95

Leise, Tanya L

2015

Volltextzugriff (PDF)

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

The Lancet (British edition), 2020-09, Vol.396 (10254), p.839-852

2020

Volltextzugriff (PDF)

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Blood, 2024-02, Vol.143 (5), p.404

2024

Volltextzugriff (PDF)

Moral Distress of Clinicians in Canadian Pediatric and Neonatal ICUs

Pediatric critical care medicine, 2020-04, Vol.21 (4), p.314

2020

Volltextzugriff (PDF)

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

BJU international, 2024-03, Vol.133 (3), p.297-304

2024

Volltextzugriff (PDF)

Quality and Safety of the Frying Oils used in Small or Medium-sized Food Enterprises in West Delhi, India

Oriental journal of chemistry, 2021-06, Vol.37 (3), p.547-552

2021

Volltextzugriff (PDF)

Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.612-612

2023

Volltextzugriff (PDF)

Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.453-453

2023

Volltextzugriff (PDF)

Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.34-34

2023

Volltextzugriff (PDF)

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7505-7505

2018

Volltextzugriff (PDF)

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Blood, 2021-11, Vol.138 (Supplement 1), p.2840-2840

2021

Volltextzugriff (PDF)

Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8037-8037

2020

Volltextzugriff (PDF)

Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20046-e20046

2020

Volltextzugriff (PDF)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Blood, 2019-11, Vol.134 (Supplement_1), p.241-241

2019

Volltextzugriff (PDF)

Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

Clinical genitourinary cancer, 2023-12, Vol.21 (6), p.e467-e473

2023

Volltextzugriff (PDF)

65 - Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S55-S56

2022

Volltextzugriff (PDF)

Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S55-S56

2022

Volltextzugriff (PDF)

Supporting Shared Resource Usage for a Diverse User Community: the OSG Experience and Lessons Learned

Journal of physics. Conference series, 2012-01, Vol.396 (3), p.32046-11

2012

Volltextzugriff (PDF)

Mental Health Hospitalizations in Canadian Children, Adolescents, and Young Adults Over the COVID-19 Pandemic

JAMA network open, 2024-07, Vol.7 (7), p.e2422833

2024

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)
Tagungsberichte
(1)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(10)
Humans
(7)
Biochemistry & Molecular Biology
(3)
General & Internal Medicine
(3)
Aged
(2)
Aged, 80 And Over
(2)
Animals
(2)
Brain Neoplasms
(2)
Clinical Trials
(2)
Communities
(2)
Hepatitis C
(2)
Immunotherapy, Adoptive - Adverse Effects
(2)
Lymphoma, Large B-Cell, Diffuse - Therapy
(2)
Male
(2)
Medicine, General & Internal
(2)
Physical Sciences
(2)
Software
(2)
Technology
(2)
Urology & Nephrology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Biodiversity inhibits parasites: Broad evidence for the dilution effect

Determination of Paraphenylenediamine in Hair Dyes Formulation Using Visible Spectroscopy

Submicron Emulsion - A Novel and Versatile Paradigm for Delivery of Therapeutics for Bioavailability Enhancement

Development of protease resistant and non-cytotoxic Jelleine analogs with enhanced broad spectrum antimicrobial efficacy

Removal of pain-relieving drugs from aqueous solutions using Octolig and selected metalloligs

Wavelet-based analysis of circadian behavioral rhythms

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Moral Distress of Clinicians in Canadian Pediatric and Neonatal ICUs

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

Quality and Safety of the Frying Oils used in Small or Medium-sized Food Enterprises in West Delhi, India

Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations

Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations

Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

65 - Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Supporting Shared Resource Usage for a Diverse User Community: the OSG Experience and Lessons Learned

Mental Health Hospitalizations in Canadian Children, Adolescents, and Young Adults Over the COVID-19 Pandemic

Suchergebnisse filtern